Trial Profile

A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OBP 801 (Primary)
Indications Anal cancer; Biliary cancer; Gallbladder cancer; Gastrointestinal cancer; Intestinal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Skin cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Oncolys BioPharma

Most Recent Events

10 Feb 2023 According to a Oncolys Biopharma media release, dose limiting toxicity was observed in phase 1 trial making it impossible to escalate the dosage to the presumed effective dose and therefore development in the field of cancer was suspended.
06 Oct 2021 Results published in the Investigational New Drugs
11 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com